Key Takeaways
- • Envision, a radiology company, and its trustee settled a class action alleging they brokered an inflated $163.7 million stock sale to the company's employee stock ownership plan (ESOP), according to a Colorado federal court filing reported by Law360.
- • The settlement came days before a bench trial was scheduled to begin, avoiding the trial.
- • The case centers on alleged ERISA-type fiduciary breaches involving the ESOP's purchase of company stock at an allegedly inflated price.
Summary
Radiology company Envision and its trustee have settled a class action alleging they brokered an inflated $163.7 million stock sale to the business' employee stock ownership plan, according to a Colorado federal court filing reported by Law360 on October 26, 2026. The settlement staved off a bench trial that was days away from starting.
The suit, brought on behalf of plan participants, accused the parties of arranging a sale of company stock to the ESOP at a price that was allegedly inflated. The source article does not disclose the settlement amount or the terms of the agreement, and the full details of the filing were behind a paywall at the time of reporting.
The resolution removes near-term litigation risk for Envision and the trustee in a matter that had been headed to a bench trial, and it is a reminder of the fiduciary scrutiny that ESOP transactions with related parties continue to attract.
The suit, brought on behalf of plan participants, accused the parties of arranging a sale of company stock to the ESOP at a price that was allegedly inflated. The source article does not disclose the settlement amount or the terms of the agreement, and the full details of the filing were behind a paywall at the time of reporting.
The resolution removes near-term litigation risk for Envision and the trustee in a matter that had been headed to a bench trial, and it is a reminder of the fiduciary scrutiny that ESOP transactions with related parties continue to attract.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.